

Special Issue

Neoadjuvant Chemotherapy for Breast Cancer

Message from the Guest Editor

One of the scientific backgrounds of neoadjuvant chemotherapy is the hypothesis that earlier treatment with the eradication of subclinical micrometastasis will improve survival. The pioneering clinical trials by the I-SPY2 working group have successfully identified the therapeutic agents through pCR improvement and established the "response predictor subtype". Still, there are a lot of unresolved issues regarding the neoadjuvant chemotherapy of breast cancer, such as the predictor of pCR, the best sequence of the therapeutic regimen, the effective treatment of non-pCR patients, the role of conventional chemotherapy in terms of immunological effect, de-escalation after pCR, and escalation therapy for non-pCR. To breast surgeons, the extent of breast surgery and the efficacy of sentinel node biopsy after NAC and the best strategy for axillary management after nodal pCR are still controversial. Through the Special Issue titled "Neoadjuvant Chemotherapy for Breast Cancer" of *Cancers*, all experts in this field are invited to contribute and submit their papers in an attempt to resolve the above issues.

Guest Editor

Dr. Shin-Cheh Chen

Breast Surgery Division, Department of General Surgery, Chang Gung Memorial Hospital at Linkou, Chang Gung University, Taoyuan 333, Taiwan

Deadline for manuscript submissions

closed (30 April 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/177282

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)